.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,178,550

« Back to Dashboard

Claims for Patent: 8,178,550

Title:Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaz- a-spiro[4.5]decan-2-one and preparation process therefor
Abstract: Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-ph- enyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.
Inventor(s): Hu; Mengwei (Washington, NJ), Paliwal; Sunil (Monroe Township, NJ), Shih; Neng-Yang (Warren, NJ), Guenter; Frank Bruno (Schachen, CH), Mergelsberg; Ingrid (Mahwah, NJ)
Assignee: OPKO Health, Inc. (Miami, FL)
Application Number:11/732,548
Patent Claims: 1. A crystalline Form I monohydrate hydrochloride salt form of the compound (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-met- hyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one (formula I): ##STR00006## wherein the crystalline Form I monohydrate hydrochloride salt form is characterized by an x-ray powder diffraction pattern including at least a strong peak having a diffraction angle (in 2.THETA.) of 21.6.+-.0.2 and lattice spacing (in .ANG.) of 4.11.+-.0.04.

2. The crystalline Form I monohydrate hydrochloride salt form of claim 1 characterized by an x-ray powder diffraction pattern having at least one additional peak selected from TABLE-US-00028 Diffraction Lattice Spacing angle (2.THETA. .+-. 0.2) RI (.ANG. .+-. 0.04) 16.1 Medium 5.49 18.4 Medium 4.83 23.5 Medium 3.78.

3. The crystalline Form I monohydrate hydrochloride salt form of claim 1 characterized by an x-ray powder diffraction pattern having at least two additional peaks selected from TABLE-US-00029 Diffraction angle Lattice Spacing (2.THETA. .+-. 0.2) RI (.ANG. .+-. 0.04) 16.1 Medium 5.49 18.4 Medium 4.83 23.5 Medium 3.78.

4. The crystalline Form I monohydrate hydrochloride salt form of claim 1 characterized by an x-ray powder diffraction pattern which includes the following peaks: TABLE-US-00030 Diffraction angle Lattice Spacing (2.THETA. .+-. 0.2) RI (.ANG. .+-. 0.04) 16.1 Medium 5.49 18.4 Medium 4.83 21.6 Strong 4.11 23.5 Medium 3.78.

5. A crystalline Form I monohydrate hydrochloride salt form of the compound (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-met- hyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one (formula I): ##STR00007## characterized by an x-ray powder diffraction pattern as shown in FIG. 1.

6. A crystalline Form I monohydrate hydrochloride salt form of the compound (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-met- hyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one (formula I): ##STR00008## wherein the crystalline Form I monohydrate hydrochloride salt form is characterized by an infrared spectrum including at least a strong peak at 1167 cm.sup.-1.

7. The crystalline Form I monohydrate hydrochloride salt form of claim 6 characterized by an infrared spectrum including at least one additional peak selected from 1693 cm.sup.-1, 1277 cm.sup.-1, 1141 cm.sup.-1, 1130 cm.sup.-1, 1094 cm.sup.-1, 703 cm.sup.-1 and 682 cm.sup.-1.

8. The crystalline Form I monohydrate hydrochloride salt form of claim 7 characterized by an infrared spectrum including at least two additional peaks selected from 1693 cm.sup.-1, 1277 cm.sup.-1, 1141 cm.sup.-1, 1130 cm.sup.-1, 1094 cm.sup.-1, 703 cm.sup.-1 and 682 cm.sup.-1.

9. The crystalline Form I monohydrate hydrochloride salt form of claim 7 characterized by an infrared spectrum including at least three additional peaks selected from 1693 cm.sup.-1, 1277 cm.sup.-1, 1141 cm.sup.-1, 1130 cm.sup.-1, 1094 cm.sup.-1, 703 cm.sup.-1 and 682 cm.sup.-1.

10. The crystalline Form I monohydrate hydrochloride salt form of claim 7 characterized by an infrared spectrum which includes the following peaks: 1693 cm.sup.-1, 1277 cm.sup.-1, 1167 cm.sup.-1 and 682 cm.sup.-1.

11. A crystalline Form I monohydrate hydrochloride salt form of the compound (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-met- hyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one (formula I): ##STR00009## characterized by an infrared spectrum as shown in FIG. 2.

12. A crystalline Form I monohydrate hydrochloride salt form of the compound (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-met- hyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one (formula I): ##STR00010## wherein the crystalline Form I monohydrate hydrochloride salt form is characterized by a Raman spectrum including at least a weak peak at 3695 cm.sup.-1.

13. The crystalline Form I monohydrate hydrochloride salt form of claim 12 characterized by a Raman spectrum including at least one additional peak selected from 3690 cm.sup.-1, 3625 cm.sup.-1, 1604 cm.sup.-1, 1032 cm.sup.-1, 997 cm.sup.-1, 724 cm.sup.-1 and 616 cm.sup.-1.

14. The crystalline Form I monohydrate hydrochloride salt form of claim 13 characterized by a Raman spectrum including at least two additional peaks selected from 3690 cm.sup.-1, 3625 cm.sup.-1, 1604 cm.sup.-1, 1032 cm.sup.-1, 997 cm.sup.-1, 724 cm.sup.-1 and 616 cm.sup.-1.

15. The crystalline Form I monohydrate hydrochloride salt form of claim 13 characterized by a Raman spectrum including at least three additional peaks selected from 3690 cm.sup.-1, 3625 cm.sup.-1, 1604 cm.sup.-1, 1032 cm.sup.-1, 997 cm.sup.-1, 724 cm.sup.-1 and 616 cm.sup.-1.

16. The crystalline Form I monohydrate hydrochloride salt form of claim 13 characterized by a Raman spectrum which includes the following peaks: 3695 cm.sup.-1, 1032 cm.sup.-1, 997 cm.sup.-1 and 724 cm.sup.-1.

17. A crystalline Form I monohydrate hydrochloride salt form of the compound (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-met- hyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one (formula I): ##STR00011## characterized by a Raman spectrum substantially as shown in FIG. 3.

18. A crystalline Form I monohydrate hydrochloride salt form of the compound (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-met- hyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one (formula I): ##STR00012## wherein the crystalline Form I monohydrate hydrochloride salt form is characterized by a differential scanning calorimetric thermogram including at least an endotherm centered at approximately 101.degree. C.

19. A crystalline Form I monohydrate hydrochloride salt form of the compound (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-met- hyl]-8-phenyl-1,7-diazaspiro[4,5]decan-2-one (formula I): ##STR00013## characterized by an differential scanning calorimetry thermogram substantially as shown in FIG. 4.

20. A pharmaceutical composition comprising a crystalline Form I monohydrate hydrochloride salt form of the compound (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one (formula I): ##STR00014## according to claim 1.

21. A pharmaceutical composition comprising a crystalline Form I monohydrate hydrochloride salt form of the compound (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one (formula I): ##STR00015## according to claim 6.

22. A pharmaceutical composition comprising a crystalline Form I monohydrate hydrochloride salt form of the compound (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one (formula I): ##STR00016## according to claim 12.

23. A pharmaceutical composition comprising a crystalline Form I monohydrate hydrochloride salt form of the compound (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-ph- enyl-1,7-diazaspiro[4,5]decan-2-one (formula I): ##STR00017## according to claim 18.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc